- Proprietary bioelectronic devices developed by Endonovo Therapeutics target patient pain and inflammation while aiding wound recovery
- SofPulse® safely decreases pain by reducing edema (swelling), which decreases the need for prescription pain medications
- Endonovo’s wearable device can be used to address an array of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue
Endonovo Therapeutics Inc. (OTCQB: ENDV) is transforming the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver Endonovo’s Electroceutical™ Therapy. Targeting inflammatory conditions in vital organs and peripheral tissues, Endonovo’s SofPulse® is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving the patient’s natural recovery experience (http://nnw.fm/O9UUp).
The efficacy of SofPulse targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue, is well documented and supported by peer-reviewed clinical research. Among the clinical findings for patients using tPEMF are decreases in post-surgery pain, a 2.2-fold reduction in the use of narcotics, vastly improved chronic wound healing and significant reductions in inflammation and edema (http://nnw.fm/Ys5NT).
Endonovo recently announced a national rollout of its SofPulse post-operative opioid alternative tPEMF therapy device to hospitals, skilled nursing centers, wound care centers and pain management clinics throughout the U.S. According to the company’s news release, Endonovo plans to be in the evaluation stage with 600 hospitals within the next 18 months, employing roughly 300 sales representatives (http://nnw.fm/nwLd6). Endonovo has also entered into an agreement to distribute its SofPulse therapy device to Veterans Administration facilities and Department of Defense health care facilities (http://nnw.fm/Z0zAx).
“We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020,” Alan Collier, Endonovo’s chief executive officer, said in the release. “With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis.”
In 2017, the U.S. Department of Health and Human Services declared a public emergency and announced a five-point strategy to combat the nationwide opioid crisis that includes advancing better practices for pain management (http://nnw.fm/WZo4k). Opioid overdoses accounted for more than 42,000 deaths in 2016, more than any previous year on record, with an estimated 40 percent of opioid overdose deaths involving a prescription opioid.
Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema and is CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
